CITY OF INDUSTRY, CA--(Marketwired - Apr 27, 2017) - Marina Biotech, Inc. (
Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail conference@jgunnar.com.
For more information and registration, please visit the conference website.
About Marina Biotech
Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 - next generation celecoxib - which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.
Contact Information:
Investor Contact
Garth Russell / Allison Soss
KCSA Strategic Communications
Phone: (212) 896-1250 / (212) 896-1267
Email: